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Abstract 
Introduction: At the peak of New Hampshire’s opioid crisis in 2016, lawmakers strategized on 
solutions. With the passage of State Bill 447, a naloxone study commission was formed to 
understand best practices around the distribution of the critical opioid reversal medication. The 
findings of the Commission became the only discussion concerning naloxone distribution despite 
the report’s call for a long-term distribution plan. Literature searches turned up no published 
reports or evaluations for the naloxone distribution program in New Hampshire. Therefore, it 
seems that state-sponsored community naloxone distribution continued through 2018 in New 
Hampshire with no formal evaluation of the program’s effectiveness. 
Methods: In order to develop an understanding of the naloxone distribution program in New 
Hampshire, a program evaluation was conducted. Because the evaluation is concerned with 
determining whether the strategies and initiatives of the naloxone distribution program have been 
met, a performance monitoring evaluation design became the philosophical construct that guided 
this work. A logic model was used to choose goals of interest and the tests associated with 
favorable program outcomes. Significant events in New Hampshire surrounding the opioid crisis 
were explored. Data for overdose deaths and naloxone distribution were the focal point of this 
project. The project collected data on distributed naloxone and opioid overdose deaths between 
the years of 2014-2018. Only 2017 and 2018 data for opioid overdose deaths were compared to 
naloxone distribution because the 2014-2016 data was incomplete. 
Results: There were 409 opioid deaths in 2017 and 399 opioid overdose deaths in 2018 in New 
Hampshire. Between 2017 and 2018, naloxone supply was increased by 38%-493%, varying 
widely across New Hampshire counties. Statistically significant increases in naloxone distributed 
to target users occurred only in Hillsborough and Strafford counties.  
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Discussion: Statistically significant changes in death rates between 2017 and 2018 did not occur 
for any comparison groups, state, or countywide. Conversely, targeted naloxone distribution 
rates differed by county. Stakeholders believe that increases in Strafford and Hillsborough 
Counties were partly attributed to the creation of SSPs in those areas occurring during the 
timeframe observed. 
Conclusions: This program evaluation sheds light on the need for better data tracking and 
transparency between organizations. According to the evaluation, maximum benefits in reducing 
opioid deaths will be realized when naloxone distribution efforts are focused in Belknap, 
Hillsborough, Strafford, Cheshire, Rockingham, and to some extent Merrimack Counties at a rate 
that is significantly higher than the rate of opioid overdose deaths. Future studies are needed to 
understand how social determinates affect the rate of opioid overdose deaths and more 
effectively target naloxone distribution. 
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Optimizing the Effectiveness of Naloxone Distribution in the State of New Hampshire:  
A Program Evaluation 
 
Problem Description 
 Between the years of 1999 and 2013, the rate of New Hampshire opioid overdose deaths 
gradually rose and then sharply increased from 2014-2017. Multiple factors contributed to this 
rapid increase, although synthetic opioid use was a primary factor according to the CDC (CDC 
Injury Center, 2019). Prescription misuse opioid overdose peaked in 2007 and has since 
remained stable (National Institute on Drug Abuse (NIDA), 2019). In stark contrast, as 
prescription overdose deaths began to level off, 2013-14 brought a spike in NH synthetic opioid-
related deaths. This trend occurred nationwide, and in 2017, 47,600 of 70,237 (~68%) deaths 
were related to synthetic opioids (NIDA, 2019). Figure 1 shows the progression of the opioid 
crisis by examining types of opioid deaths between 1999 and 2019. 
Figure 1.  New Hampshire drug overdose deaths by overdose category (NIDA, 2019) 
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 A critical intervention to reduce opioid-related overdoses is naloxone access (Penn 
Leonard Davis Institute of Health Economics, 2019). According to the United States Surgeon 
General, naloxone awareness and targeted education and distribution are integral to reducing 
opioid-related deaths (Office of the Surgeon General, 2018). On June 2, 2015, the State of New 
Hampshire approved House Bill 271, authorizing standing orders for opioid antagonists like 
naloxone (Narcan ®). HB 271 also included a provision allowing organizations to possess, store, 
or distribute naloxone. The bill protects individuals that use the medication to aid persons who 
overdose on opioids (Gencourt State of NH, 2015). Months later, HB 270 went into effect 
granting immunity from arrest, prosecution, and conviction for those who witness and request 
medical assistance for persons who have sustained an opioid overdose. New Hampshire House 
Bills 270 and 271, in conjunction with the “Good Samaritan Law” RSA 508:12, protect those 
who witness an emergency or crime and may come to the aid of victims without fear of liability 
if the assistance results in an injury or death. Specifically, Section 318-B:28-b of the Controlled 
Drug Act protects individuals who request medical assistance for persons overdosing from being 
arrested and charged with possession of illicit substances. These changes marked New 
Hampshire’s legislative steps to addressing the state’s rising opioid death rates (Gencourt State 
of NH, 2015; Section 508:12 Aid at Scene of Emergency or to Victim of Crime., 1985).  
 At the peak of the state’s opioid crisis, lawmakers again strategized on solutions to the 
opioid epidemic. They passed Senate Bill 447, Establishing a Commission to Study Narcan® 
(An Act establishing a commission to study Narcan, 2016). The Commission’s Final Report 
cited six recommendations on naloxone and its distribution fulfilling the Commission’s role 
outlined in SB447:  
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1. Discouraged the creation of a Narcan Registry recording demographics of individuals 
who obtained Narcan  
2. Did not endorse requirements for additional training on administration or dosing,  
3. Rejected the implementation of mandatory reporting systems 
4. Found that treating individuals who overdosed with Narcan should be supported in 
engaging with recovery services but not required to participate 
5. Guided additional training material for inclusion in Narcan kits such as legal information 
surrounding overdoses and calling 911  
6. Recommended improved access and responsive distribution of Narcan and training for 
both community and law enforcement to more effectively reach those at the highest risk 
for overdose (NH Commission to Study Narcan, 2017) 
The commission report concluded by summarizing the naloxone distribution quantities 
from October 2015 through October 2017. The Commission found that the state distributed 
12,136 units to community groups and health agencies. Furthermore, the report stated, “greater 
availability of Narcan has greater potential to prevent opiate overdose-related deaths,” and called 
for further investigation into whether supplies and distribution were meeting community needs 
(NH Commission to Study Narcan, 2017). The findings of the Commission’s Final Report were 
the only state discussion concerning the distribution of naloxone despite a call in the report for 
the committee to produce a long-term distribution plan (An Act establishing a commission to 
study Narcan, 2016). Legislative policy changes were compiled and organized into a timeline for 
reference in Figure 2.  
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Literature searches turned up no published reports or evaluations for the naloxone 
distribution program in New Hampshire. Therefore, it seems that state-sponsored, community 
naloxone distribution continued through 2018 in New Hampshire with no formal evaluation of 
the program’s effectiveness. Program evaluation is essential to ensure fiscal responsibility and 
the ability to meet goals and objectives by process and outcome examination (Milstead, 2016).  
The absence of viable program metrics and outcome measures did not deter the state from 
changing its naloxone distribution model when it transferred responsibility for distribution to the 
newly adopted Doorway hub and spoke framework beginning in early 2019. Data regarding 
program efficacy should inform future decision making (Centers for Disease Control and 
Prevention, Program Performance and Evaluation Office, 2019). 
 The purpose of this project was to describe the structure, process, and outcomes of New 
Hampshire’s state-sponsored community naloxone distribution program, focusing on 
Figure 2.  Critical events in the opioid legislative and response timeline 
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associations between opioid overdose death rates and naloxone access and distribution. Analysis 
from this evaluation produced recommendations to optimize naloxone distribution.  Findings 
were disseminated to stakeholders to highlight naloxone program successes and areas of 
opportunity to inform future quality improvement projects and the promotion of evidence-based 
practice. 
Available Knowledge  
Naloxone, an opioid reversal drug or opioid antagonist, was approved by the Food and 
Drug Administration (FDA) for intravenous and intramuscular pharmaceutical use in the United 
States in 1971 (American Chemical Society, 2016). The medication works by binding to the 
same receptors that opioids bind. Fortunately, mu receptors have a higher affinity for naloxone 
which make the drug so effective at reversing the dangerous respiratory and central nervous 
system depression that opioids produce, thus allowing a temporary 20-90-minute reprieve from 
the deadly effects of opioid overdose (Harm Reduction Coalition, n.d.; Jordan & Morrisonponce, 
2019). Developed in 2012, intranasal naloxone was finally approved by the FDA in 2015. FDA 
approval coincided with New Hampshire’s Standing Order Bill allowing widespread naloxone 
distribution (American Chemical Society, 2016).  
 Widespread naloxone distribution is crucial. States with naloxone access and Good 
Samaritan Laws have been shown to exhibit statistically significant reductions in opioid-
overdose mortality by 14% and 15%, respectively (McClellan et al., 2018). The McClellan et al. 
2018 study compared states having Good Samaritan and favorable naloxone legislation to those 
who did not have Good Samaritan Laws between the years 2002 and 2014. Studies show that 
naloxone distribution by laypersons is cost-effective (Coffin & Sullivan, 2013; Langham et al., 
2018; Open Society Foundations, 2013).  Depending on the delivery method, naloxone can range 
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from between $40-$89 per dose with generic versions hovering around the $40 mark (LaVito, 
2019). To lower costs even further, in April 2019, the FDA approved the first generic naloxone 
hydrochloride nasal spray (US Food and Drug Administration, 2019). A focus on cost reduction 
has been central to the philosophy of making naloxone available for everyone at risk for an 
opioid overdose. The U.S. Surgeon General, a strong advocate for the opioid reversal 
medication, states that naloxone should be carried by anyone who knows someone at risk for 
overdose (LaVito, 2019).   
 New Hampshire has received grant funding for naloxone from the Substance Abuse and 
Mental Health Services Administration through STR (State Targeted Response) and SABG 
(Substance Abuse and Treatment Block), SOR (State Opioid Response) grants with the majority 
of federal grant monies distributed through the New Hampshire Bureau of Drug and Alcohol 
Services (BDAS) (Bipartisan Policy Center, 2018). The New Hampshire Department of Safety 
also received an $800,000 grant to train first responders to administer naloxone and provided 
10,000, two-dose Narcan kits to at-risk individuals accessible via several alternatives (Carbone, 
2017; US Department of Health and Human Services, n.d.).  
In 2017-18, New Hampshire used $12,000 of STR funds for naloxone distribution and 
$600,000 for the Department of Corrections naloxone distribution (Bipartisan Policy Center, 
2018). New Hampshire Medicaid spending on naloxone increased from $2,572 in 2016 to a 
projected $15,000+ in 2018 (Bipartisan Policy Center, 2018). Despite the costs associated with 
naloxone training and distribution, cost-benefit analysis traditionally shows promise for 
decreasing overall health care expenditures for these prevention measures. One study states that 
layperson distribution of naloxone increases quality-adjusted life years (QALY) and costs far 
less than what is considered a traditional cost-effectiveness threshold for medical interventions 
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(Coffin & Sullivan, 2013). Markov models that evaluate probabilities using modeling for 
randomly evolving systems have demonstrated cost-effectiveness in all conducted analyses 
(Open Society Foundations, 2013). According to the Institute for Clinical and Economic Review, 
the average value attributed to one QALY is between $50,000-$150,000, the cost attached to one 
year of perfect health (Institute for Clinical and Economic Review, 2019). Cost-effective 
treatment includes anything costing less than this threshold for each QALY gained. Although the 
use of QALY is controversial and, as some state, “built on value-judgments,” it has been useful 
for testing the quality and value-added benefits for health interventions (Institute for Clinical and 
Economic Review, 2019; Smith, 2019). Modeling shows that in the US, naloxone costs between 
$421 and $2429 per life-year gain in populations with opioid use disorder (Open Society 
Foundations, 2013). The higher-end dollar amounts include not only naloxone but also consider 
the price associated with expenditures for the criminal justice system and healthcare research 
(Open Society Foundations, 2013). 
Community-based naloxone distribution is estimated to have averted over 10,000 opioid-
overdoses in the past two decades in the US (Jordan & Morrisonponce, 2019). The World Health 
Organization states that people who use drugs (PWUD) have a lifetime prevalence of 70% for a 
witnessed drug overdose; the majority are attributable to opioids (World Health Organization, 
2018). In New Hampshire, according to the Bipartisan Policy Center, Naloxone community 
training has been provided to 25,000 individuals (Bipartisan Policy Center, 2018). From 2012-
2016, Narcan prescriptions in New Hampshire have increased from 877 to 2793 doses (Carbone, 
2017). Increased naloxone distribution and education about its use tripled the life-saving 
opportunities and chances for recovery in New Hampshire (Carbone, 2017). Access to naloxone 
and training on its use is also critical for bystanders witnessing an opioid overdose. Non-
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randomized studies show that these individuals can and do reverse overdoses in the community 
when provided with both naloxone kits and training (Clark et al., 2014). 
In determining the most cost-effective means of naloxone distribution, it is vital to 
understand the target populations at risk for overdose and the barriers to dispersal. Lagisetty, 
Bohnert, & Fendrick (2018), stated that it is more important to strategically target those at-risk 
individuals who will receive the most benefit from naloxone distribution and training rather than 
broad population-based application. Reporting shows that although rural areas face similar 
problems related to opioid use and death, naloxone distribution programs in urban cities are more 
likely to connect with individuals most in need of the reversal drug (Doleac & Mukherjee, 2019). 
The logic that densely populated cities provide more opportunities for bystanders to administer 
naloxone and shorter emergency service response times provide support to bolster programs in 
urban areas. In 2017, Rockingham and Hillsborough Counties, the two largest by population in 
NH, experienced the highest number of drug deaths at rates of 31.66 and 47.59 per 100,000 
people, respectively (Duval, 2017). 
Targeted distribution of naloxone requires an understanding of the benefits of geographic 
distribution efficacy but also usage and target populations that are at the highest risk for overdose 
and how to connect them to naloxone. Evidence shows that there are two main categories of at-
risk opioid users- those who misuse opioids prescribed by their health care provider and those 
who use illicit opioids (street derived heroin and fentanyl) for non-medically prescribed purposes 
(Lagisetty et al., 2018). The American Society of Addiction Medicine (ASAM) adds individuals 
with an opioid use disorder but who are currently in recovery, to the list of targeted recipients 
(ASAM, 2016). Targeting individuals and communities at high risk and providing opioid 
education and naloxone distribution (OEND) has been linked to death rates that are 26-46% 
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lower when compared with areas not implementing OEND practices (Walley et al., 2013). 
 Multiple sources report universal naloxone distribution targeting high-risk opioid users to 
be best practice (Lagisetty et al., 2018; World Health Organization, 2018). Availability through 
pharmacies in New York was described as “spotty” (Correal, 2018), and a formal exploration of 
availability in New Hampshire pharmacies has not been undertaken. Opioid consumers have 
reservations about accessing naloxone via pharmacies; feelings of stigmatization and pharmacies 
lack supplies, and knowledge regarding dispensing protocols makes this mode of distribution 
less than satisfactory (Lagisetty et al., 2018). The most successful and patient-centered 
distribution locations include “high-yield venues” like emergency rooms, syringe service 
programs (SSPs), and treatment facilities that engage opioid consumers at a higher frequency 
(Lagisetty et al., 2018). In 2019, New Hampshire opened The Doorway as part of the state’s new 
“hub and spoke” program to better meet the needs of patients with substance use disorders 
(Wickham, 2019). Utilizing funds from the SOR grant, the Doorway program provides treatment 
referrals, clinical evaluations, and naloxone at any of their 9 locations around the state. Another 
mode of naloxone delivery at the community level includes five SSPs operating in cities around 
NH. Figure 3 represents the various means of accessing naloxone in the state.  
Figure 3: Accessing Naloxone in New Hampshire 
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Despite the legislative strides improving accessibility of naloxone and increased funding 
for opioid treatment and recovery, the CDC reports that 467 people still died of drug overdoses 
in 2017, placing New Hampshire in the top five states for drug overdose mortality statistics 
nationwide (CDC Injury Center, 2019). Interesting to note, the New Hampshire Office of the 
Chief Medical Examiner’s Drug Death Data report issued on October 16, 2019, reveals 
incongruencies between the CDC data and the actual drug overdose-related death count in the 
state. Due to state upgrades to case management software, previously unrecorded data bumps 
overdose death totals to 490 people in 2017 (NH Office of the Chief Medical Examiner, 2019). 
Inconsistencies add confusion to already difficult to measure outcomes for opioid-related deaths. 
Also, the data related to the effectiveness of the state’s naloxone program has not been 
thoroughly evaluated. Neither the State Board of Pharmacy nor the NH Hospital Association 
monitors the use and distribution of Narcan (Carbone, 2017). The only publicly available data set 
has been EMS administration of naloxone, which does not include administration by community 
members necessitating examination of state-funded, community naloxone doses with objective 
outcome measures. 
 In June 2017, the BDAS provided a framework for Naloxone distribution circulating the 
“Naloxone Distribution Information for Regional Public Health Network Partners” information 
guide (BDAS, 2017).  The guidelines included background information on state legislative 
changes and reviewed the supports for public health network partners in their efforts to provide a 
distribution and training program for naloxone. The report included recommendations for 
distribution, access to training for educators and end-users, and how to acquire naloxone, but 
intended outcomes to measure the success of the initiative were not discussed. 
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 Historically, substantial evidence backs the efficacy and cost-effectiveness of naloxone 
distribution programs. In New Hampshire, utilization of program evaluation tools to understand 
and refine the structure, process, outcomes, and cost-effectiveness of naloxone distribution has 
not publicly been examined and looking at how community distribution affects opioid death is 
needed. The purpose of a naloxone program evaluation in New Hampshire would serve to 
describe the current state while focusing on the utility and effectiveness of the current 
distribution model for targeting at-risk populations to reduce opioid deaths and provide 
recommendations for improvement. The development of program goals and viable target 
outcomes would provide measures of program success and inform future health policy decisions. 
Rationale 
The Center for Disease Control and Prevention endorses program evaluation to promote 
continuous quality improvement and reduce the cost of health care by ensuring that data drives 
decisions when making financial investments in public policy and programing (Centers for 
Disease Control and Prevention, Program Performance and Evaluation Office, 2019). The CDC’s 
Framework for Program Evaluation guided a systematic evaluation of naloxone distribution to 
assess the impact and effectiveness related to costs and outcomes in the State of New Hampshire. 
Appendix A provides the CDC’s visual depiction of the stepwise evaluation process that includes 
describing the stakeholders, the program, the design and methodologies, development of 
program data concerning best practice evidence, and established policy to justify conclusions and 
recommendations. 
 This program evaluation looked at community naloxone distribution from a process and 
outcome standpoint.  Because the evaluation is concerned with determining whether strategies 
and initiatives have been met, a performance monitoring evaluation design became the  
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philosopical construct which guided this work.  According to the W.F. Kellogg Foundation, 
performance monitoring design ensures accountability, well-managed utilization of program 
resources, and promotes transparency in tracking progress toward pre-established goals while 
alerting stakeholders promptly of deficiencies (W.K. Kellogg Foundation, 2017). This design 
was appropriate because it has the flexibility to be conducted throughout a program’s lifespan 
and can answer whether program efforts have been conducted as planned and met original goals 
(W.K. Kellogg Foundation, 2017).  
Due to the unpredictability and quickly changing environment around health promotion 
and policy for the opioid epidemic, this program evaluation design progressed from a 
developmental evaluation (DE) perspective.  DE embraces the philosophy of supporting 
innovation and promoting continuous quality improvement in an environment that requires 
adaptivity (W.K. Kellogg Foundation, 2017).  DE recognizes that engaging in frequent program 
evaluation provides benefits from enhanced creativity and responsiveness to environmental 
changes by a continuous refinement of processes (W.K. Kellogg Foundation, 2017). The 
utilization of formal program evaluation for New Hampshire’s community naloxone distribution 
program aligns with federal policy. In 2011, President Barack Obama signed the Government 
Performance and Results Modernization Act requiring federal agencies to perform program 
evaluations to effectively communicate achievement and improve program outcomes 
(SAMHSA, 2014). As a result, SAMHSA evaluations collect and report on findings promoting 
transparency related to the performance of federally funded programs. State programs receiving 
federal dollars through grants and funding matches also require evaluation (Milstead, 2016). The 
NALOXONE PROGRAM EVALUATION  17 
absence of comprehensive program evaluation for naloxone distribution in New Hampshire, 
which is funded both by Medicaid and block grant dollars, represents a quality gap.  
Specific Aim 
The purpose of this program evaluation was to describe the current state of New 
Hampshire’s community naloxone distribution model using the CDC Program Evaluation 
Model. Associations between opioid overdose death rates and naloxone access and distribution 
were analyzed. The data analysis provided insight helping formulate recommendations to 
optimize naloxone distribution in the community. Findings were disseminated to stakeholders to 
highlight naloxone program successes and areas of opportunity to inform future quality 
improvement projects and the promotion of evidence-based program development. Figure 4 
summarizes the project objectives in detail.  
 
 
Figure 5.  Proposed project objectives. 
Figure 4. Detailed description of project objectives. 
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Methods 
Context 
 This project reviewed opioid overdose deaths in New Hampshire and the accessibility of 
community naloxone. In 2017, 2.3% or 3,000 individuals in New Hampshire aged 18-25 had an 
opioid use disorder (SAMHSA, 2019). For individuals over 25 years old, 1.4% or 16,000 had an 
opioid use disorder (Substance Abuse and Mental Health Services Administration, 2019). The 
State of New Hampshire has a population of 1.36 million dispersed throughout ten counties. It is 
the 42nd most populous state, 21st when compared by its size and population density. The 
largest city in New Hampshire is Manchester, with a 2010 census population of 109,565, 
followed by Nashua with a population of 87,970. The northern third of the state has high poverty 
rates and comprises only 5% of the total population (New Hampshire Population, 2019).  
Interventions 
 The CDC program evaluation guide recommends the construction of a logic model to 
visualize the associations between program goals and resources, activities, outputs, and short and 
long-term outcome measures needed to meet those objectives (Centers for Disease Control and 
Prevention, Program Performance and Evaluation Office, 2019). Logic models engage the 
evaluators in the “Describing the Program” step of the CDC model. Available knowledge and 
guidance from stakeholders familiar with the New Hampshire naloxone distribution program 
allowed for the retrospective construction of goals and purposes that would be appropriate for 
this program evaluation. Program goals precipitated various realistic short and long-term 
objectives to guide the evaluation and create a post-factum logic model, see Appendix B 
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Data Collection Plan   
 In order to guide this evaluation, the logic model was used to choose goals of interest and 
the tests associated with favorable program outcomes. Significant events in New Hampshire 
surrounding the opioid crisis were explored. Data for overdose deaths and naloxone distribution 
were the focal point of this project. The project collected data on distributed naloxone between 
the years of 2014-2018. There was a specific focus on state-funded community accessible 
naloxone, defined as kits provided directly to end-users, those at risk of an overdose, or persons 
potentially witnessing an overdose situation. Community naloxone distribution data was 
obtained from the New Hampshire Harm Reduction Coalition (NHHRC).  
The NHHRC requested and received various data and statistics related to naloxone 
distribution from the New Hampshire Department of Health and Human Services Office of Legal 
and Regulatory Services under the Freedom of Information Act (FOIA). Data from the FOIA 
included naloxone distribution by provider type, town/county, and cost. The data also contained 
information related to training and program goals for advertising and marketing. Naloxone is 
also administered through emergency medical services, and this information was gathered using 
public data sets available from the Bureau of Drug and Alcohol Services (BDAS) and the New 
Hampshire Department of Health and Human Services (DHHS) Drug Monitoring Initiative. 
EMS and ED data shed light on the effectiveness of community naloxone distribution as 
hypothesized decreases in these usage categories are expected to be related to increasing 
naloxone access in the community. In order to understand the structure of the naloxone 
distribution program, a Google search was conducted using the question “Where can I get 
naloxone in New Hampshire?” The search served the purpose of assessing the various 
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distribution access points to end-users. The access points for community users will be contrasted 
with the access points discussed in Figure 3. 
Opioid death data and legislative policy changes pertinent to naloxone distribution and its 
relationship with state law were gathered to provide context. State practices were compared to 
best practice evidence gathered using resources gathered from the literature search. Opioid-
related death data was requested from the New Hampshire Office of the Medical Examiner 
(OCME) heretofore referred to as “OCME direct data.” The request looked specifically for data 
outlining the town where the opioid overdose occurred in addition to the place of death, which 
may be geographically unique and whether the overdose was intentional, as in the case of 
suicides.  Evaluator used a Google Search to gather opioid death data from the CDC and to seek 
out any data and information related to opioid deaths not provided from the listed sources: 
including emergency medical services (EMS) data, emergency department (ED) utilization data, 
census data, and CDC handbooks and information on best practice. The New Hampshire Office 
of Strategic Initiatives’ webpage provided yearly population estimates (NH Office of Strategic 
Initiatives, 2019). 
Qualitative and experiential data was collected from evaluator’s interactions with 
participants and volunteers at a Manchester, NH SSP. Interactions led to a more nuanced picture 
of how community naloxone distribution impacts target users.  Informal communication relevant 
to the opioid epidemic was captured. 
Data Analysis Plan 
 The evaluator examined data to understand the relationship between opioid overdose 
death (excluding suicides) and community naloxone distribution patterns. The information 
depicted in the New Hampshire opioid crisis timeline was utilized to search for potential 
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correlations between opioid overdose death and legislative initiatives that involve public 
naloxone distribution programs. This evaluation used two data sets from the OCME, drug death 
data from the Office of the Chief Medical Examiner from 2014 to 2019 available online, and the 
direct data set that included all drug deaths by county from 2017-2018. OCME direct data was 
organized by type of drug overdose and whether the death was accidental or suicide. Only New 
Hampshire drug death data was used. Suicides and undetermined deaths were also excluded. 
Opioid deaths were separated from non-opioid deaths because of the potential for overdose 
reversal using naloxone for opioids.   
           Naloxone distribution data were categorized according to the type of distribution program. 
The evaluation attempted to differentiate between doses intended for the target population of 
opioid users by grouping the FOIA naloxone dataset into categories. For instance, each entry in 
the “Agency Type” column was divided into one of 5 groupings, Community Event, Community 
Health, SSP and Substance Use Treatment Programs (SUTP), and Agency Use. It was assumed 
that state-funded community naloxone intended for SSP and SUTP would reach the target group 
of opioid users, whereas the other categories were less likely to end up in the hands of people 
with Opioid Use Disorder or those with a strong likelihood of witnessing an overdose. The 
“Agency Use” category designates organizations that intended to use naloxone in their facility. 
The “Agency Use” category included schools receiving minimal (1-2 doses) quantities of 
naloxone for emergency administration. This categorization enabled analysis of the effect of 
targeted distribution to people who use opioids and whether targeted distribution affects opioid 
overdose mortality. State-funded kits sent to schools and police departments were typically 
returned due to expiration, meaning that target users did not access agency use kits. Therefore, 
agency use kits would not be useful in improving the target outcomes. 
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            A quantitative evaluation of opioid-related death data was made using JMP statistical 
analysis software and Microsoft Excel. The software facilitated the exploration of correlations 
between opioid deaths and naloxone distribution per county using naloxone distribution datasets 
from the NHHRC FOIA request and the OCME drug death data. The methodology was iterative 
based on the quality and quantity of data obtained from state and national sources. Microsoft 
Excel Student’s T-test calculations ascertained statistical significance when a probability statistic 
was p<0.05.  
Advocacy 
      The findings of this project were disseminated to stakeholders, including the NHHRC. The 
project is interested in disseminating findings and, by using gap analysis, intends to provide 
recommendations for optimization of naloxone distribution. Also, the project plan includes 
understanding the stakeholders’ intentions to utilize these findings to close distribution gaps and 
initiate the best practice. 
Ethical Considerations 
      The data used in this project had no individual identifiers. The project evaluation makes 
limitations and conflicts of interest subject to full disclosure. The evaluator will respectfully 
engage with stakeholders from Queen City Exchange SSP, NHHRC and other community 
groups in a non-threatening manner that eliminates the potential for emotional harm or distress. 
The author has no conflicts of interest to declare. 
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Results 
 Collected drug death data from OCME was evaluated. Data from the years between 
2014-2016 did not include cause of death (suicide vs. accidental), county, or detailed toxicology 
reports. More detailed information was included in the reports from the 2017 and 2018 datasets. 
Opioid Deaths were parsed out from total drug deaths from 2014-2019, and these were plotted in 
Figure 5. The 2019 data point in Figure 5 is incomplete due to 5 deaths pending toxicology.  
 
 
Figure 5 shows that total drug deaths, the sum of those with toxicology indicating overdose from 
substances other than opioids such as cocaine and methamphetamine and opioids follow a 
similar curve as opioid only overdose death. Between 2014 and 2019, opioid overdose drug 























Drug Deaths vs. Opioid Deaths
including suicide and undetermined 
Drug Deaths Opioid Deaths
* Toxicology Data Pending Data Incomplete
Figure 5. State of New Hampshire opioid overdose death data  (data source NH OCME Drug 
Death Data Sheets) 
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graph in Figure 5 shows that all drug deaths and opioid drug deaths have decreased since the 
peak in 2017.      
           The 2017-18 drug death data directly from the OCME direct data contained specific 
content allowing for the extraction of valuable information and the exclusion of deaths that 
would not be affected by naloxone. These breakouts were not provided on the Drug Death Data 
Sheets available through the Department of Justice OCME website. Seven drug deaths in other 
states were excluded in the 2017-2018 dataset: one Maine, which was also a suicide, one 
Massachusetts, and five Vermont death, one of which was a vehicle accident. Two unknown 
counties were excluded as were two natural deaths, 13 undetermined causes, and 68 suicides. 
The unknown county exclusions canceled each other, one from 2017 and the other from 2018 
data. 
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Overall, exclusions included 94 deaths from the medical examiner’s dataset as non-relevant to 
the state and not likely to be affected by naloxone for reversal.  
   After accounting for all exclusions and removing all non-opioid related deaths from the 
dataset, there were 409 opioid deaths in 2017 and 399 opioid overdose deaths in 2018 in New 
Hampshire. This data does not indicate a statistically significant reduction in deaths, p=0.92; 
95% CI [-4.98, 5.48]. Figure 6 shows the sum of 2017 and 2018 county deaths at a rate of death 
per 100,000 people. This Pareto illustrates that deaths in Belknap County are the most prevalent, 
followed by Hillsborough and Strafford counties.According to the graph, maximum benefits in 
reducing opioid deaths will be realized when naloxone distribution efforts are focused in 
Belknap, Hillsborough, Strafford, Cheshire, Rockingham, and to some extent Merrimack 
Counties. 
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Figure 6 only includes accidental overdose deaths pulled from the OCME direct data set. Figure 
7 further breaks out OCME opioid overdose deaths per 100,000 people for each county 
visualizing increases and decreases between 2017 and 2018. Figure 7 highlights increases in 
opioid deaths for Belknap (3% increase), Cheshire (21% increase), Merrimack (22% increase), 
and Sullivan (74% increase) Counties.  
The second batch of data pertains to naloxone distribution. There were 776 naloxone 
shipments with a total of 28,453 kits distributed and remaining in circulation between September 
16, 2015, and March 26, 2019.  Kits that were removed from circulation were returned for being 
damaged or unused. The most common reason for return was expiration. Naloxone data from the 
FOIA request was sorted and categorized into usage groupings, Table 1.  There were 432 
naloxone kits shipped to five Doorways locations on December 31, 2018.  These kits were 
excluded from the dataset due to the low chance of the facilities using the kits within the outlined 
evaluation period. The remaining naloxone distribution data were sorted into five groups based 
on Agency Type receiving the shipment, “Agency Use,” “Community Events,” “Substance Use 
Treatment (SUT),” “Syringe Service Programs (SSP),” and “Community Health.” Agency Use 
naloxone was delivered to different organizations with the intention that supplies would be 
utilized by staff. It is hypothesized that SSPs and SUT programs are the most likely to provide 
preventative naloxone to target users.  This group would have the highest potential for opioid 
overdose reversal (Lagisetty et al., 2018). Table 1 shows a decrease in the Agency Use naloxone 
shipments between 2017 and 2018 from 59 to 39. Community Events and Community Health 
naloxone need also declined from 41 to 21 and 57 to 48 shipments, respectively, in the same 
period. Both SSP and SUT shipments increased from 2017-2018.  SSP shipments climbed from 2 
to 17 and SST from 56 to 92. 
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According to a BDAS stakeholder, community naloxone kits cost around $74 a box, 
which contains two 2 mg nasal intranasal inhalers. The combined sum of all use naloxone for 
2017 and 2018 was 15,845 kits. The approximated cost for the kits at the stated price is 
$1,172,530. If we only account for targeted kits, those that will provide the highest likelihood of 
reducing overdose, the sum for 2017-18 is 1061 kits at the cost of $707,514.  
           The program evaluation analyzed community naloxone distribution, analyzing trends, and 
decreases in death based on naloxone access. Figure 8 shows the yearly amount of total naloxone 
distributed per 100,000 persons for each county in New Hampshire. T-tests show that the only 
statistically significant change in total naloxone distribution is for Strafford County, where 
p=0.046.  In Strafford County, total naloxone distribution per 100,000 persons increased from 
776 kits to 1,625. The evaluation also attempted to understand the changes in targeted access to 
naloxone across counties.  Figure 9 explores the changes between 2017-18 of naloxone put into 
Year 2017 2018 2017 2018 2017 2018 2017 2018 2017 2018













Recovery Centers Project 439 Safe Stations
Office Use Shelters






Police Church Programs Drug Courts Hand Up Hospitals
Table 1. 
 Community Naloxone Distribution Categories  
 
 
Note. Total shipments are calculated by year for each category. Shipments could range from one 
kit to over 100 kits. 
 
NALOXONE PROGRAM EVALUATION  28 
the hands of target users. The graph shows that there were across the board increases in targeted 
naloxone delivered by SUT and SSP in all counties except for Coos.  
    
     
Naloxone supply was increased by 38%-493% across New Hampshire counties. The 
graph reports data in kits per 100,000 people and also relates the associated percent decrease in 
opioid overdose deaths between 2017-2018. The most substantial reductions were seen in Coos 
and Grafton with 51% and 22% decrease in opioid overdose deaths, respectively. The highest 
increases in opioid deaths were seen in Cheshire and Merrimack counties. It is of note that only 
Hillsborough and Strafford Counties had a statistically significant increase in targeted naloxone 
Figure 8. Naloxone Distribution by County per 100,000 people calculated by multiplying 
the total number of kits distributed in a county by 100,000 and dividing by the county’s 
population. 
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with p=0.0487 and p=0.0182, respectively.   
 
An essential aspect of this evaluation was to compare deaths to community naloxone 
distribution. Figure 10 shows opioid overdose deaths plotted against naloxone distribution types 
in a stacked bar graph. This graph utilizes OCME direct death data for opioid overdose, 
excluding suicides, undetermined, natural, and vehicle deaths as well as deaths from other states. 
Data from 2017-2018, seen here broken into quarters and bars and then subdivided into 
distribution modes, SUT, SSP, Community Event, or Community Health. Community Event and 
Community Health naloxone distribution decreased between 2017 and 2018, whereas SSP and 
SUT distribution increased over the same period. The death data shows a decreasing trend but no 
statistically significant decrease, p=0.63, for opioid deaths between 2017 and 2018. The median 























































Figure 9. Targeted Naloxone per 100,000 people calculated by multiplying the total number of 
kits distributed in a county by 100,000 and dividing by the county’s population. T-test statistics 
* indicates p value <0.05 
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Figure 10. Death to Distribution. This figure shows data from OCME and the FOIA requests 
compiled to illustrate how community naloxone distribution and opioid overdose death data 
compared between 2017 and 2018 
 
Figures 11 and 12 depict bivariate models comparing opioid deaths to the total number of  
kits, all distribution methods, and opioid deaths to targeted naloxone distribution, respectively.   
Each data point within the figures depicts quarterly opioid deaths and kits distributed statewide.  
There is no correlation between the variables of naloxone distribution and death, either targeted 
naloxone or otherwise, between the years of 2017 and 2018. With respective p values of 0.32 and 
0.20, indicates that the fitted line explains no variation, and there is not a relationship between x 
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Figure 12. Scatterplot of naloxone kits targeted to end users compared to opioid overdose deaths 





RSquare Adj 0.313031 
Root Mean Square Error 10.29352 
Mean of Response 10.8 
Observations (or Sum Wgts) 80 
RSquare 0.197066 
RSquare Adj 0.186772 
Root Mean Square Error 11.19958 
Mean of Response 10.8 
Observations (or Sum Wgts) 80 
Figure 11. Scatterplot of naloxone kits to opioid overdose deaths by quarter for 2017-2018 
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 Looking at Bivariate analysis is only one piece of the picture. A run chart provides a 
deeper dive into the OCME direct data for opioid overdose. Run charts are essential tools for DE 
and continuous improvement because they monitor trends and predict patterns. Figure 13 shows 
direct data plotted in a run chart.  The points at which SSPs are implemented in various counties 
are added for reference. Of note are the drops in deaths occurring shortly after each SSP county 
began distributing naloxone. Although correlation does not equate to causation it is an interesting 
finding. Also, of note is an astronomical point with 54 deaths in July 2018. Whether this was an 
increase in drug potency or something else would need further evaluation. There is a total of 7 
runs for this run chart which is indicative of a signal of change. Without OCME direct data for 
2019 it is difficult to see if this becomes a shift in the dataset which would indicate the median 
may have changed and that the intervention of community naloxone distribution may be having a 
non-random effect on the process. Run charts were also used to evaluate EMS data. 
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   Although EMS data is not considered part of the community naloxone distribution, 
understanding trends in EMS administration of naloxone is worthwhile as a marker of overdose 
incidence. The evaluation was interested in determining any potential relationships between 
EMS reversal data and naloxone and overdose in New Hampshire. EMS data measures 
emergency access to naloxone given to individuals for decreased alertness, meaning there may 
be administrations that are not tied to opioid overdose. Overall, EMS naloxone distribution has 
been decreasing since 2016, see Figure 14. All New Hampshire counties except for Cheshire had 
decreased EMS naloxone administration from 2017-2018, see Figure 15. There was a statistically 
significant decrease in EMS naloxone administration between 2017 and 2018 (p=0.011). 
According to the New Hampshire Bureau of Emergency Medical Services, heroin and non-
heroin opioid EMS overdose responses decreased by 423 and 12, respectively, between 2017 and 
2018, (Center for Excellence, 2019). 
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Source: NH Bureau of EMS
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       Emergency room visits related to opioid use were investigated, but the opioid overdoses 
were not separated from other opioid-related visits in the data set (Center for Excellence, 2019).  
The Governor’s Commission Report on Alcohol and Other Drugs Mid-Year Report did state that 




 The purpose of this program evaluation was to describe the current state of New 
Hampshire’s community naloxone distribution model. Associations between opioid overdose 
death rates and naloxone access and distribution were analyzed at both the state and county 
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Figure 15. EMS naloxone administration per county per 10,000 population (Data source: NH 
Bureau of EMS) 
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had on opioid overdose deaths. EMS data was also gathered. State legislative and policy changes 
were reviewed to understand further the implications for the naloxone distribution program in the 
state. 
           The program evaluation utilized the CDC framework, engaging stakeholders directly 
involved with the New Hampshire BDAS, New Hampshire Harm Reduction Coalition, and SSP 
volunteers and participants. Stakeholder engagement provided perspective allowing for the 
creation of a logic model to understand the relationships between the resources, activities, and 
outputs of short- and long-term outcomes and how best to test for successful implementation. 
           The evaluation focused on tests that were deemed useful in accomplishing goals of 
decreased morbidity and mortality for people who use opioids in the state of New Hampshire. 
Opioid overdose deaths, community naloxone distribution, and reduction in EMS naloxone 
administration, and to a smaller extent, ED visits between 2017 and 2018 were analyzed. 
Analysis of death data showed a decrease of only 10 opioid overdose deaths at the state level. 
Death rates between the counties varied widely. Statistically significant changes in death rates 
between 2017 and 2018 did not occur for any comparison groups, state, or countywide. 
Conversely, targeted naloxone distribution rates differed by county. Statistically significant 
increases were only seen in Hillsborough and Strafford Counties. Stakeholders believe that this 
was partly attributed to the creation of SSPs in those areas occurring during the timeframe 
observed. During the evaluation’s timeframe, SSP and SUT naloxone shipments increased, and 
shipments for Community Health and Community Events decreased.  Multiple counties and 
state-level regression analyses showed no relationship between the variables of targeted 
naloxone and opioid overdose death for the evaluation period. 
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           Strengths of the evaluation include a thorough review of the literature that gave 
perspective for a system-level framework depicted in a logic model. After a thorough search was 
conducted, and many stakeholders were approached for information on the topic, it was 
determined that no such model existed for the state-funded, naloxone distribution program.  
Logic models can focus a program, and the creation of a logic model strengthened the focus of 
the evaluation (Centers for Disease Control and Prevention, Program Performance and 
Evaluation Office, 2019). The program was evaluated based on “tests” outlined in the logic 
model by assessors unrelated to the project, and therefore there is a low risk of bias, cognitive, 
confirmation, statistical, or otherwise related to any conflicts of interest. Statistics were 
independently checked by three separate assessors whom all agreed that no relationships could 
be found between community naloxone distribution and opioid overdose death between 2017 and 
2018. The Run chart for accidental opioid overdose did show that there was some type of change 
in the death dataset. Run chart evaluation with 2019 data will hopefully provide more conclusive 
insight into potential shifts or trends on the run chart. 
Interpretation 
 ASAM recommends targeted naloxone distribution to persons at high risk of witnessing 
or having an opioid overdose (American Society of Addiction Medicine, 2019). Studies show 
that naloxone is cost-effective (Coffin & Sullivan, 2013) and reduces opioid deaths (Bird et al., 
2016; Walley et al., 2013) provided target users have access to kits and proper training (Clark et 
al., 2014). Although this evaluation did not provide evidence for a statistical reduction in opioid 
overdose deaths, there was a statewide decrease in opioid overdose deaths. Attributing the 
reduction in deaths solely to naloxone distribution is not recommended. Many confounding 
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variables, anomalous data, and, more obviously, antithetical trends were uncovered during the 
evaluation.  
 Before 2017, there was a dramatic decline in the rate of opioid prescriptions, see 
Appendix D (NIDA, 2019). Data for the opioid prescribing rate was not readily available to 
account for the time frame of this evaluation. Decreasing prescriptions could have a varying 
effect on the opioid death rate unrelated to naloxone. One plausible scenario may be that those 
decreasing opioid prescriptions, coupled with cheap illicit alternatives, drove more people to 
black-market sources of pain management (Dasgupta et al., 2018). These factors potentially 
boosted the opioid overdose death rates, especially for synthetic opioid overdose. Although 
Dasgupta et al. suggest that the decreases in prescription opioids did not result in a decrease in 
prescription death, therefore, it is more likely the latter alternative. The complex interplay 
between prescription opioids and illicit pain management alternatives that have filled a gap result 
in an interesting confounding variable. 
 Another possible confounder is people who use drugs (PWUD) increasing awareness of 
current market trends in drug supply potency. Drug deaths in 2017 hit their peak, with most of 
these deaths attributed to the synthetic opioid fentanyl (NIDA, 2019).  Fentanyl use is most 
commonly found in the communities of Hillsborough and Strafford counties (Marsch, 2017). 
There are conflicting thoughts as to whether a lack of awareness was a driver for increasing 
opioid deaths or that deaths were attributed to people actively seeking fentanyl (Marsch, 2017). 
The argument that a lack of awareness caused an increase in overdose deaths may explain a 
modest decrease in deaths in 2018. Anecdotal evidence from the Queen City Exchange 
participants in Manchester, NH, suggests that awareness of fentanyl in the supply chain is now 
almost universal. When asked, “What drugs are you injecting?” clients will answer fentanyl or 
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reply, “Heroin. Well, it is all fentanyl now anyway, isn’t it?” Participants have a keen awareness 
of the supply market now, as corroborated by Marsh 2017. Other anecdotal reports from 
stakeholders suggest that during these periods of increased drug potency, “There is a higher self-
reported rate of opioid reversals using naloxone and that these reversal statistics seem to decrease 
by the next week as participants become aware of the supply potency,” SSP volunteer.  
 Two additional factors that possibly impact the evaluation of naloxone’s effect are 
suicides and incidence of opioid use. If the incidence of opioid drug use is increasing over time, 
the overall effect of community naloxone distribution may appear less effective. Rising 
incidence rates may negate the visible naloxone gains in reducing opioid overdose deaths. This is 
a challenging statistic to obtain but it is worth mentioning as a possible confounding variable. 
Another data confounder is suicide. There is a community of thought that suicides may be 
undercounted (Dasgupta et al., 2018).  Accounting for this possibility would mean that there 
would be fewer accidental deaths than presently reported.  For the 2017-2018 year, there were 68 
suicides and 13 unknown causes of death.  These numbers could conceivably be higher, meaning 
fewer accidental overdoses than reported, allowing for a higher chance of opioid reversals 
utilizing naloxone.   
           There are perplexing anomalies in the data where counties that had minimal increases in 
targeted naloxone distribution have the most significant decreases in death.  Coos County, for 
instance, had a 51% decrease in opioid overdose death while not increasing its targeted naloxone 
at all.  There were no state-funded community naloxone shipments to SUT during this period, 
and SSPs do not exist in this county.  
One aspect to note that may be important for future naloxone distribution patterns is the 
age demographic of people who use opioids. According to the NH OCME in 2017, 20-39-year-
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old people were the largest cohort of opioid overdose deaths. Population demographics show that 
Coos and other northern New Hampshire counties had older median ages than southern counties 
see Appendix E. Coos and Grafton had the highest percent decreases in opioid deaths and some 
of the quantities of targeted naloxone. Age and other social demographics may play a part in this 
phenomenon, but this is outside of the scope of this evaluation. It may be worthwhile to examine 
larger forces about what causes a community/population to engage in drug use (i.e. poverty, 
unemployment, lack of social capital, high rates of undertreated mental health disorders) in 
future studies.  
           The creation of SSPs in the state brought about a shift in the ability to distribute naloxone 
to the target user group. Belknap County, described as a “resource desert,” had the highest opioid 
overdose death rate. This county would be a prime choice to implement an SSP program. SSPs 
began distributing in Grafton County and Strafford County the third quarter of 2017.  
Strafford County SSPs began receiving their own shipments of naloxone in first quarter 
of 2018.  Prior to this they were distributed through The Health and Safety Council of Strafford 
County which was categorized as Substance Use Treatment distribution category. Hillsborough 
was the final county to initiate an SSP program, but the program did not receive shipments of 
naloxone kits from the state until the second quarter of 2018. Due to lag times between 
organizations receipt of shipments and delivery to the end-user, it is unclear how many kits were 
accessible during the early months of 2018, so it is unclear whether SSPs will have a significant 
impact on opioid overdose reversal under the present distribution system. Based on evidence 
from studies that show favorable results from widespread access to naloxone, especially 
naloxone in the hands of target users, it is hypothesized that the SSP distribution of naloxone will 
have an effect, but it is yet to be realized (Walley et al., 2013).  
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 The Walley et al., 2013 study showed that opioid overdose deaths decrease at a kit 
delivery rate exceeding 100 per 100,000 persons. Another study states that the optimal naloxone 
kit target number should be 14 times a cities overdose death rate (Madah-Amiri et al., 2017). 
Rates this high were only achieved three times throughout the evaluation period, 2017 in Carroll 
and Hillsborough, and 2018 in Rockingham. In a final example, a study investigating naloxone 
cost-effectiveness found that 101 naloxone kits would need to be distributed to prevent one death 
(Open Society Foundation, 2013). Open Society Foundation continues, stating that making 
naloxone accessible to 20% of heroin users would decrease the rate of overdose deaths by 10.6% 
in the first 5 years of a program. Each county did see non-statistically significant decreases in 
opioid overdose deaths. A greater effect may have been observed if the targeted naloxone 
distribution rate was 14 times more than the opioid overdose death rates. Even at distribution 
rates of 101 per opioid overdose death, naloxone distribution would be cost-effective for the 
State of New Hampshire. 
 One challenge for the New Hampshire naloxone program was that widespread 
community access was reliant on the state’s policy to work solely with the Department of Health 
and Human Services (DHHS) funded providers.  A stakeholder lamented that “Because the state 
only distributed to DHHS-funded treatment/recovery providers (but had no restrictions on ‘social 
safety agencies’), areas that were resource deserts (Keene and to a lesser extent Laconia/Tilton) 
got much worse over time,” (Anonymous personal conversation 2020). The higher death rates in 
these counties may have been a byproduct of this decision. Successful program models have had 
specific target distribution quantities. Studies from Scotland and Massachusetts have shown 
success when setting distribution targets, kits per number of deaths or naloxone education and 
distribution rates per population, opioid overdose deaths declined (Bird et al., 2016; Walley et 
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al., 2013). The Bird et al., 2016 study showed that kit distribution rates of nine times the number 
of opioid overdose deaths reduced the rate of their target population, post-prison release persons, 
by 36% (Bird et al., 2016). 
 Cost-benefit analysis is a necessary aspect of any program evaluation, establishing that 
naloxone programs cost approximately $421 and $2429 per life-year gain in populations with 
opioid use disorder (Open Society Foundations, 2013).  Part of the education given to 
participants at SSP and other training programs is that when witnessing an overdose, it is vital to 
call 911 (New Hampshire Harm Reduction Coalition, 2017). Despite this recommendation, 
anecdotal data from SSP participants suggests that there is still fear about calling 911. 
Participants often report, “We didn’t call we just used more Narcan,” and “Nah, we didn’t want 
any trouble. The Narcan worked, so it was all good.” EMS opioid reversal data shows a decrease 
in 911 calls between 2017 and 2018 by approximately 435 responses (Center for Excellence, 
2019). The average cost of ambulance transport in NH is between $800 and $1200 (Marchocki, 
2015; New Hampshire Insurance Department, n.d.).  At a conservative estimate of $1000 per 
transport, the savings between 2017 and 2018 could be up to $435,000. Whether or not this could 
be partially or wholly in relationship with naloxone administration is a topic for future study. If 
calculated out, similar comparisons could be made for ED cost savings if data on opioid 
overdose. ED cost savings include cost of resuscitation efforts, costly ICU hospitalizations for 
anoxic brain injuries, losses for worker productivity, and bereavement costs (Florence et al., 
2016; Premier, 2019). 
Limitations 
 This program evaluation project would have benefited from a collaboratively designed 
logic model in coordination with stakeholders at BDAS. Collaboration produces a thoroughly 
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comprehensive framework for accurately measuring the effectiveness of agreed-upon outcomes 
of importance.  It would also have helped to discuss in detail the Agency Use categories for 
which the naloxone distribution data was sorted.  Evaluators made reasonably accurate 
assumptions about whether organizations receiving naloxone were in Community Event, 
Community Health, SST, or SSP groupings. However, without precise recordkeeping from each 
organization, it is difficult to understand whether naloxone was ending up with target users. 
           It is unknown whether the organizational distribution of naloxone occurred within a 
reasonable amount of time from the ship date. Naloxone shipped in mid-July 2018 may have 
been warehoused until the end of 2018 or late, making it impossible for these kits to affect the 
opioid overdose death rates.  The assumption that naloxone shipment dispersal occurred within 
no more than a few months-time post shipments and were in the possession of target-users lacks 
validation and is, therefore, another limitation of the project.  
 It was challenging to obtain direct death data.  The OCME was only able to provide 
comprehensive overdose death data from 2017 and 2018 due to changes in recordkeeping and 
databases.  The original plan was to look at death data from 2014-2018. Ideally, a comparison 
between 2016-17 and 2018-19 would have been ideal to more accurately capture the changes in 
distribution models that SSP and SST focus created. 
 Interestingly, the CDC data for opioid deaths, Figure 1, did not align with the New 
Hampshire opioid overdose death data from the Death Data Sheets, Figure 5.  Discrepancies 
possibly result from the lack of inclusion of pending toxicology deaths in the CDC data.  
Conversely, this evaluation excluded several data points and is unsure if this was the discrepancy 
between the death data sheets and this report. Other state data and vehicle deaths not affected by 
naloxone should skew the overall death tallies. Categorization errors make the death datasheets 
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questionable, warranting further evaluation and interviews to understand the discrepancies. Drug 
death and naloxone distribution data underwent multiple screenings and statistical reviews by 
independent reviewers.  
 Confounding variables affecting internal validity were discussed. They included 
interconnections between prescription drugs and inexpensive illicit drugs affecting opioid 
overdose deaths, how drug market knowledge and understanding drug potency may have 
increased over time, and how these factors worked to prevent overdoses. Another potential 
confounder is the idea that the rate of opioid use disorder could have been increasing at a 
dramatic rate therefore causing more people to use potentially deadly drugs and overdose, so 
even if naloxone distribution were successful in saving lives, the total number of overdose deaths 
was not dramatically reduced.  Social determinates presenting confounding variables must be 
considered. Finally, the evaluation discussed how undercounting suicides would confound opioid 
overdose datasets. 
           There are positive factors that promote external validity and detractors, as well. The lack 
of multiple years of data detracts from the usefulness of community access to naloxone. Each 
study found in the Available Knowledge section shows that community naloxone distribution 
should have a more significant effect than demonstrated here.  Despite this, the evaluation 
highlights many areas for improvement in record keeping and data tracking that makes the work 
highly generalizable. One of the biggest strengths of the evaluation is in recognizing the capacity 
for DE and implementing a continuous quality improvement plan and universal data tracking for 
all naloxone distribution organizations that utilize a logic model to meet target outcomes. 
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Conclusions 
 This program evaluation consisted of a two-phase process. In the first phase, the current 
state of New Hampshire’s community naloxone distribution was described, and the associations 
between opioid overdose death rates and naloxone access and distribution were analyzed. No 
apparent correlations between opioid overdose death and community naloxone distribution could 
be obtained based on the statistical analysis. 
 The data and information gathered throughout the evaluation were used to formulate 
recommendations to optimize naloxone distribution in the community further. The main 
recommendations include 1. improving transparency and data tracking 2. improving knowledge 
about county opioid use demographics and social determinants, and 3. using standard outcome 
measures to understand progress toward meeting statewide program goals. 
 This program evaluation sheds light on the need for better data tracking and transparency 
between organizations. It was exceedingly difficult for the New Hampshire Harm Reduction 
Coalition stakeholders to gather critical information related to naloxone distribution and death. 
There were multiple queries and requests submitted before obtaining data. Data reporting must 
reflect a consistent effort across all stakeholder programs to account for naloxone kits, and 
opioid overdose deaths, and this information should be easily accessible. Transparency is 
required for DE and continuous quality improvement.  Implementation of run charts will help 
track trends and shifts alerting stakeholders of variation that may indicate changes in processes 
of interest. 
 The CDC recommends that programs utilize a logic model to guide program evaluation 
for all projects that utilize public health dollars. New Hampshire’s state-funded naloxone 
distribution program is no exception.  Program goals should be acknowledged and easily 
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accessible. There were stipulations on who could be involved in state-level meetings and policy 
decisions around naloxone distribution (Bureau of Drug and Alcohol Services, 2017). The state, 
according to the Naloxone Distribution Information for Regional Health Partners, also placed 
prerequisites around who was permitted to distribute naloxone (Office of the Inspector General, 
2019). Open policy for distribution is beneficial, providing organizations produce transparent, 
accurate, and consistent data management practices that align with state program goals and target 
outcomes.  
 In order to reduce confounding in the data sets, individual identifiers for participants and 
large-scale studies are needed to track naloxone usage at the target user level. Identifiers will 
help to understand demographic confounders and allow predictive distribution instead of 
flooding areas where there may not be a need. This prospect is challenging because of the 
necessity to protect anonymity of participants utilizing SSP services. If possible, studies should 
provide analysis of participant usage patterns, statistics for numbers of kits per reversal, and 
information about EMS use. To gather high-quality data requires direct questions and interrater 
reliability of surveyors, which is less likely when doing convenience sampling. Carefully 
designed studies are less prone to bias and the researcher’s interpretation demonstrating greater 
internal and external validity. Participants must understand the impact of poor data and the 
repercussions of inflating or underestimating the usefulness of naloxone. The information 
gathered from carefully conducted studies can be used to strategically target distribution and 
reduce costs by eliminating waste of expired products and random distribution to people unlikely 
to encounter an opioid overdose. Information from population and opioid use studies in the state 
can pinpoint hot spots that would benefit from naloxone outreach programs such as SSPs.   
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  Cost-effective distribution is imperative for the sustainability and effective management 
of the state-funded naloxone program. Studies looking at cost-effectiveness stressed the 
importance of adequate distribution in order to see decreases in death. New Hampshire is below 
evidence-based distribution targets. The state should work with organizations to achieve the most 
cost-effective alternatives and widespread distribution models for naloxone kits. This way, 
valuable resources can be funneled into other harm reduction activities, treatment programs, or 
used for the development of much-needed programs in underserved areas.  
 This program evaluation gave an unbiased look at the history, data, and efforts of New 
Hampshire’s state-funded community naloxone distribution program between 2017 and 2018. 
The recommendations and interpretations from this evaluation can guide stakeholders when 
using a developmental evaluation perspective to support innovative study and continuous quality 
improvement. This practice will optimize the access and distribution of naloxone to decrease 
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New Hampshire Community Naloxone Distribution Program Post-Factum Logic Model Design
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New Hampshire Age Adjusted Opioid Prescription Overdose Deaths and Opioid Prescription 
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